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Abstract
PURPOSE—Aromatase inhibitors (AI), which decrease circulating estradiol concentrations in 
post-menopausal women, are associated with toxicities that limit adherence. Approximately one-
third of patients will tolerate a different AI after not tolerating the first. We report the effect of 
crossover from exemestane to letrozole or vice-versa on patient-reported outcomes (PROs) and 
whether the success of crossover is due to lack of estrogen suppression.
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METHODS—Postmenopausal women enrolled on a prospective trial initiating AI therapy for 
early-stage breast cancer were randomized to exemestane or letrozole. Those that discontinued for 
intolerance were offered protocol-directed crossover to the other AI after a washout period. 
Changes in PROs, including pain (Visual Analog Scale [VAS]) and functional status (Health 
Assessment Questionnaire [HAQ]), were compared after 3 months on the first versus the second 
AI. Estradioland drug concentrations were measured.
RESULTS—Eighty-three patients participated in the crossover protocol, of whom 91.3% reported 
improvement in symptoms prior to starting the second AI. Functional status worsened less after 3 
months with the second AI (HAQ mean change AI #1: 0.2 [SD 0.41] vs. AI #2: −0.05 [SD 0.36]; 
p=0.001); change in pain scores was similar between the first and second AI (VAS mean change 
AI #1: 0.8 [SD 2.7] vs. AI #2: −0.2 [SD 2.8]; p=0.19). No statistical differences in estradiol or 
drug concentrations were found between those that continued or discontinued AI after crossover.
CONCLUSIONS—Although all AIs act via the same mechanism, a subset of patients intolerant 
to one AI report improved PROs with a different one. The mechanism of this tolerance remains 
unknown, but does not appear to be due to nonadherence to, or insufficient estrogen suppression 
by, the second AI.
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INTRODUCTION
Selective aromatase inhibitors (AIs) decrease circulating estrogen concentration in post-
menopausal women by preventing conversion of adrenal-derived precursors to estradiol and 
estrone in peripheral tissue [1]. AIs have been shown to be more effective than the selective 
receptor modulator tamoxifen in the adjuvant and metastatic settings [2, 3]. However, 
tolerance of AI therapy can be poor due to treatment-emergent toxicities, primarily AI-
induced musculoskeletal symptoms (AIMSS), which can lead to early discontinuation [4, 5].
It is desirable for patients to continue treatment with adjuvant endocrine therapy for the 
optimal duration in order to maximize breast cancer outcomes [6]. In the adjuvant setting, 
we and others have reported that some patients intolerant of an initially-prescribed AI persist 
with a second AI treatment [4, 7, 8]. In the Exemestane and Letrozole Pharmacogenetics 
(ELPh) trial, conducted by the Consortium on Breast Cancer Pharmacogenomics (COBRA), 
women with ER positive early stage breast cancer were randomly assigned to either adjuvant 
letrozole or exemestane. In a substudy, we observed that approximately one-third of women 
intolerant of the first AI were able to tolerate the second after a brief wash-out period [4]. 
Since all AIs act via the same mechanism and have similar toxicity profiles, it is unclear why 
patients intolerant of one AI would be able to tolerate a different one. In addition, it is 
unknown which patients are more likely to tolerate a second AI medication. In this report, 
we further characterize the patient-reported outcomes (PROs) and serum estradiol and drug 
concentrations during treatment with the first versus second AI medications in the ELPh trial 
to gain further insights into the mechanisms of this tolerance and of the patient experience 
following the switch from one AI to another.
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MATERIALS AND METHODS
Study Participants
Postmenopausal women were eligible for enrollment on the ELPh trial if they had stage 0–
III hormone receptor-positive breast cancer and were initiating treatment with an AI. Details 
of the trial have been previously published (clinicaltrials.gov NCT00228956)[4, 9]. Prior to 
enrollment, all indicated surgery, chemotherapy, and/or radiation therapy was completed. 
Prior tamoxifen therapy was permitted. No prior AI therapy for any reason was allowed. 
Institutional Review Board approval was obtained at all three participating sites (Johns 
Hopkins University, Indiana University, University of Michigan). Before undergoing 
protocol-directed procedures, patients were required to provide written informed consent.
Study Procedures
Patients were randomized 1:1to treatment with letrozole (Femara; Novartis, Basel, 
Switzerland) 2.5 mg orally daily or exemestane (Aromasin; Pfizer, New York, NY) 25 mg 
orally daily. After 132 patients had been enrolled, an amendment to the protocol allowed 
patients with self-reported intolerance to the AI to which they were originally randomized to 
crossover to the other study-provided AI. Following crossover, patients discontinued the first 
AI medication and remained off therapy during a washout period of 2–8 weeks per protocol. 
Following the washout, patients started treatment on the second AI until discontinuation for 
any reason or completion of study follow-up.
Blood samples were collected at baseline and at 3 months on the first AI and after 1–3 
months on the second AI for evaluation of serum estradiol and drug concentration. Serum 
samples were assayed for estradiol using an ultrasensitive gas chromatography tandem mass 
spectroscopy assay as previously described [10]; the lower limit of quantification (LLOQ) of 
this assay was 0.625 pg/mL. Letrozole and exemestane concentrations were measured by 
mass spectrometry as previously described [11–13].
PROs, described below, were obtained before and during treatment with the first AI, at the 
time of discontinuation of the first AI, and at baseline and 3 months following initiation of 
the second AI. The objective of the current PRO analysis was to compare the differences in 
early changes in symptom burden (3 months to baseline) during treatment with the first and 
second AI (Online Supplement 1). The medical record was queried to record the date of 
discontinuation of the second AI therapy if the patient stopped treatment after the end of the 
6-monthcrossover period, or the date of last follow-up.
Validated tools to measure pain (Visual Analog Scale [VAS]), functional status (modified 
Health Assessment Questionnaire [HAQ])[14], health-related quality of life (EuroQOL 
VAS)[15], depression (Center for Epidemiologic Studies–Depression [CESD])[16], anxiety 
(Hospital Anxiety and Depression Scale [HADS-A])[17], and symptom burden [18] were 
utilized. Clinically significant change in symptom burden was defined as a change of at least 
2.0 points for the pain VAS and 0.22 points for the HAQ. [19, 20]. For symptom burden, as 
previously described [21], we derived six separate symptom clusters (musculoskeletal, 
mood, vasomotor, cognitive, weight/body image, and vulvovaginal) from a 47-item tool, 
composed largely of items from the Breast Cancer Prevention Trial Symptom Checklist [18]. 
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Scores for each item ranged from 0 to 4, with a higher score indicating worse symptom 
burden. In addition to the above instruments, patients completed two questions, “Do you still 
have the symptoms that you had when you were taking the first study medication?” and “Do 
you currently have any bone, joint, or muscle pain?” at baseline (following washout), 1, 3, 
and 6 months following crossover to the second AI medication.
STATISTICAL CONSIDERATIONS
In this exploratory analysis of patients who crossed over from one AI medication to another 
because of intolerance, we examined the difference in pain, functional status, quality-of-life, 
depression, anxiety, and symptom burden during treatment on the two different AI 
medications. For all PROs except the EuroQOL and the two single-item crossover questions, 
mean change scores from baseline to 3 months were calculated such that a negative mean 
change in each PRO indicated the score decreased from baseline (improved) and a positive 
mean change in each PRO indicated the score increased from baseline (worsened). For the 
EuroQOL, a negative mean change from baseline to 3 months indicated QOL worsened and 
a positive mean change QOL improved. The PRO scores were compared within patients 
between their first and second AI using the Wilcoxon signed rank test. PRO evaluation was 
considered missing at any time point after the patient had discontinued either AI. The two 
crossover questionnaire responses were analyzed descriptively.
The differences in estradiol and drug concentrations at 1–3 months of the second AI therapy 
between those that continued and discontinued the second AI were assessed using Wilcoxon 
rank sum test.
Multiple comparisons were not controlled for due to the exploratory nature of the analysis. 
P<0.05 was considered statistically significant.
RESULTS
Patient Characteristics
Of the 83 patients who discontinued the first AI medication and agreed to participate in the 
crossover study, 34 (41%) initially treated with letrozole switched to exemestane, and 49 
(59%) initially treated with exemestane switched to letrozole; the proportions of those who 
started with each AI and switched was not statistically significantly different (p=0.10) 
(Figure 1). As previously reported [4], approximately one-third of patients who were unable 
to tolerate a first AI persisted in taking the second. Baseline characteristics for all the 
eligible patients in the current analysis are listed in Table 1.
Serum Estradiol and Drug Concentrations following Crossover
Estradiol and drug concentrations were analyzed following crossover to assess if there were 
pharmacodynamic and pharmacokinetic differences that would provide insight into patient 
tolerance of AI therapy following crossover. Of the 83 patients enrolled in the crossover 
study, 66 (80%) had estradiol concentrations assessed 1–3 months after initiation of 
treatment with the second AI (Figure 1). Forty-nine of the 83 (59%) patients had estradiol 
concentrations assessed both 1–3 months after initiation of treatment with the second AI and 
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3 months after the first AI. Thirty-eight of 49 (77.6%) patients had estradiol concentrations 
below the LLOQ during treatment with both AI #1 and #2 (Figure 2A). Six of 49 (12.2%) 
patients’ estradiol concentrations increased to above the LLOQ during AI #2, four of 49 
(8.2%) patients’ decreased to below the LLOQ after switching therapy and one (2%) 
remained above the LLOQ during treatment with both AI medications. There was no 
difference in estradiol concentrations between those that continued or discontinued after 
crossover to letrozole (p=0.15) or exemestane (p=0.27). Similarly, there was no difference in 
drug concentrations between those that continued or discontinued after crossover to letrozole 
(p=0.39) or exemestane (p=0.53) (Figure 2B). Estradiol and drug concentrations were not 
available from the remaining 34 subjects because of technical errors or inability to obtain 
blood.
Change in Symptom Burden During Treatment with the Second AI
Immediately following the washout period (baseline) and serially during treatment with the 
second AI, patients were queried about (1) change in symptoms compared to the first AI 
medication (Figure 3A) and (2) current bone, joint, or muscle pain (Figure 3B). When 
queried about change in symptoms during the washout period, 9 of 46 responding patients 
(19.5%) reported no longer having the symptoms they had while on the first AI and 33 
(71.7%) reported improved symptoms. Five of 48 responding patients (10.4%) reported no 
bone, joint, or muscle pain and 18 (37.5%) reported mild symptoms at the initiation of the 
second AI medication. After 6 months, 3 of the 35 patients (8.5%) who remained on the 
second AI medication continued to report no bone, joint, or muscle pain and 13 (37%) 
reported mild symptoms.
Differences in Patient-Reported Outcomes During First versus Second AI Medications
As shown in Online Supplement 1, PROs were assessed prior to initiation of therapy 
(baseline) and after 3 months of treatment with the first AI medication and at the same time 
points before and during treatment with the second AI medication. Compared to the first AI, 
during the first 3 months of treatment with the second AI medication patients reported 
statistically significantly less worsening of functional status (HAQ mean change AI #1: 0.20 
[SD 0.41] vs. AI #2: −0.05 [SD 0.36]; p=0.001) (Table 2). No statistically significant 
difference in the change in pain VAS or musculoskeletal cluster was observed when 
comparing symptoms during the initial 3 months of treatment with the first and second AI.
Depression worsened significantly less during the initial 3 months of treatment with the 
second AI medication compared to the same time period during treatment with the first AI 
(mean change CESD AI #1: 1.3 [SD 8.3] vs. AI #2: 0.2 [SD 6.8]; p=0.03). Similarly, 
analysis of the mood symptom cluster showed that patients reported development of fewer 
adverse mood symptoms during the first 3 months on the second AI compared to the first AI 
(mean change AI #1: 0.2 [SD 0.5] vs. AI #2: 0 [SD 0.2]; p=0.02). In addition, as compared 
to the first AI, patients reported statistically significantly less worsening of vasomotor 
symptoms during the first 3 months of treatment with the second AI (mean change AI #1: 
0.2 [SD 0.7] vs. AI #2: −0.2 [SD 0.7]; p=0.01). No other statistically significant differences 
were observed between changes in PROs during the first compared to the second AI.
Kadakia et al. Page 5
Breast Cancer Res Treat. Author manuscript; available in PMC 2018 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
DISCUSSION
In the current analysis of the ELPh trial, using prospectively collected PROs in a protocol-
directed crossover substudy, we observed that patients who had discontinued initial 
treatment with one AI medication because of toxicity were less likely to report negative 
impacts on functional status, depression, and vasomotor symptoms during treatment with an 
alternate AI medication. These findings were noted even though both AIs act via the same 
mechanism of action and have similar side effect profiles.
Several possible mechanisms might explain these curious findings. First, if AIMSS and 
other toxicities of the AIs are due to extremely low estradiol concentration, it is possible that 
if the second AI is less effective in lowering estradiol concentrations than the first, this could 
result in improved tolerance of the second AI medication. Our data do not support this 
theory. In the crossover cohort, there were no differences in circulating estradiol 
concentrations after 1–3 months of treatment between those who ultimately persisted on the 
second AI medication and those who discontinued treatment because of toxicity.
A second possible explanation for apparent tolerance of the second AI is non-compliance 
with treatment. However, examination of serum drug concentrations during treatment 
demonstrated similar concentrations in those that continued and those that discontinued the 
second AI. In addition, if a patient was not taking the medication as directed then her 
estradiol concentration would be expected to be greater, which, as described above, was not 
what was observed. Therefore almost all patients were likely taking the medication as 
reported.
A third possibility might involve inherited germline pharmacogenomics, resulting in 
differences in drug metabolism, estrogen signaling, or tolerance of associated pain. We 
previously reported an association between a specific single nucleotide polymorphism in the 
gene encoding estrogen receptor alpha and decreased persistence with exemestane but not 
letrozole, although this finding has not yet been independently verified [22]. Further, one 
might postulate that off-target effects account for the tolerance of one drug, but not the other. 
However, although slightly higher for exemestane vs. letrozole, a large proportion of patients 
in both initial groups were unable to tolerate one or the other, and we observed tolerance of 
the second AI regardless of the initially assigned AI medication.
The washout period itself may allow for improved compliance by some unclear physiologic 
change in symptom perception after a short break in toxicity, or alternatively, simply a 
psychological one. Indeed, in our study, 91% of patients reported improved or resolved 
symptoms following the washout period (Figure 3B). Similarly, in the ATOLL trial, patients 
reported improvements in pain and functional status following a 1 month washout period 
[23]. However, our study was not powered to reliably explore any associations between 
improvement in pain symptoms following washout and duration of therapy on the second AI 
medication. If the improvement is due to a physiologicor a psychologic mechanism, it 
should not matter what AI was started as the “second” treatment – either an alternative (such 
as in the ELPh trial) or the same drug as initially assigned. To our knowledge, no study has 
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formally tested if restarting the same AI after a brief period of discontinuation would 
similarly lead to improved tolerance of the AI medication.
On the other hand, greater patient willingness to proceed with next line therapy might 
influence subsequent tolerance. Multiple studies have shown that most patients are willing to 
accept adjuvant therapy even with minimal efficacy [24, 25]. However, limited data exist to 
support that patients remain similarly accepting if they discontinue prior adjuvant treatment 
due to toxicity. Unexpectedly, symptom severity on the first AI was higher in those that 
pursued crossover than those who declined (data not shown) suggesting that the degree of 
toxicity does not influence willingness to consider an alternate AI.
A key strength of the ELPh trial is the prospective collection of PROs during AI therapy 
both before and after the crossover event. In addition, and in contrast to previously reported 
experiences of crossover from one AI to another, the current analysis provided a comparison 
of switching from a steroidal to a non-steroidal AI, and vice-versa, as well as assessment of 
circulating biomarkers. Limitations of this analysis include the small sample size, short 
duration of follow up after crossover, lack of randomization to crossover versus not, and 
missing data. All three previously reported crossover studies similarly limited follow-up to 6 
months [7, 8, 23]. Future research examining the impact of crossover on long-term tolerance 
of medication, or intermittent discontinuation of treatment, may reveal additional 
information about factors limiting tolerance of this class of medication.
In summary, we compared PROs in a prospective study of patients who were intolerant to 
initial AI therapy and who switched to a different AI and evaluated if any such variance 
might be related to differences in estradiol suppression. Despite finding no significant 
difference in circulating estradiol concentrations, patients reported modestly fewer 
symptomson the second AI medication compared to the first. This study provides additional 
evidence that switching from one AI to another is an option for managing bothersome 
treatment-emergent symptoms and that the mechanism for this tolerance is unlikely to be 
related to a differential effect on estradiol suppression between AIs. A greater understanding 
of why an individual patient can tolerate one AI better than another may yield insights into 
initial treatment selection and optimize compliance with minimal impact on quality of life 
for breast cancer survivors.
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Figure 1. Consort Diagram
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Figure 2. Serum estradiol (E2) and drug concentrations 1–3 months after initiation of the second 
AI
Exemestane (E) is represented by solid circles and letrozole (L) by open circles. Columns 
designate whether patients switched from E to L, or vice versa, and are divided by whether 
patients persisted on (continued) or discontinued the second AI medication by the 6-month 
time point. (A) Serum E2 concentrations. The lower limit of quantification (LLOQ) was 
0.625 pg/mL. (B) Serum letrozole and exemestane concentrations.
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Figure 3. Patient reported symptoms during treatment with the second AI medication
(A) Responses to “Do you still have the symptoms that you had when you were taking the 
first study medication?” (B) Responses to “Do you currently have any bone, joint, or muscle 
pain?” N: number.
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Table 1
Patient Characteristics
All Patients (N=500) Crossover
(N=83)
Variables No. (%) No. (%)
Median Age (Range) 59 (35–89) 60 (37–80)
Race Caucasian 441 (88.2) 76 (91.6)
Other 59 (11.8) 7 (8.4)
Mean body mass index (SD) 29.9 (6.4) 30.5 (6.2)
Initial AI Letrozole 252 (50.4) 34 (41)
Exemestane 248 (49.6) 49 (59)
Prior Chemotherapy Any 228 (45.6) 37 (44.6)
Prior Tamoxifen 184 (36.9) 25 (30.1)
Time on First AI, months Median (95% log-log CI)1 23.7 (23.6–23.8) 6.8 (5.8 – 9.0)
Last VAS Score on First AI, Median (Range) 3.45 (0–10) 5.5 (0–10)
Last HAQ Score on First AI, Median (Range) 0.13 (0–2.5) 0.25 (0–2.1)
1Study duration was 24 months and patients may have continued AI beyond study completion at discretion of MD
AI: aromatase inhibitor. CI: confidence interval. SD: standard deviation.
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